In another safety concern over a long-approved drug, Roche has been
forced to add new warnings to its anti-transplant rejection drug
CellCept (mycophenolate mofetil (MMF)) amid the news that it is
associated with increased risk of...
Roche heard early this morning that the European Commission (EC)
has decided to reinstate the marketing authorisation for the
company's HIV drug, Viracept (nelfinavir), but countries outside
the EU have yet to make a final decision.
Roche announced its third quarter financials today, with its
portfolio of oncology products such as Herceptin (trastuzumab) and
Avastin (bevacizumab) performing strongly, and helping off-set the
massive 60 per cent drop in Tamiflu...
European regulators have recommended that Roche's marketing
authorisation for HIV drug Viracept (nelfinavir) be reinstated,
following serious good manufacturing practice (GMP) deviations that
caused toxic contamination of drug...
Roche has just had the child-size, lower strength version of its
blockbuster flu treatment Tamiflu (oseltamivir) approved by EU
authorities, though possibly just a little too late for this year's
The latest act in the Viracept (nelfinavir) debacle has seen Roche
officially lose marketing authorisation for the HIV treatment,
following reports of high levels of genotoxic contamination in the
Roche has received a positive opinion from EU regulators
recommending the approval of low-dose capsules of the blockbuster
flu drug Tamiflu (oseltamivir), providing a more convenient dosage
form for children.
In the latest episode of the Viracept contamination case, the drug
is now at risk of losing its marketing authorisation across Europe
while the dangers posed by the chemical contaminant are established
and manufacturer Roche rectifies...
Just over a week after Roche was forced to initiate a Europe-wide
recall of HIV drug Viracept (nelfinavir), in-PharmaTechnologist.com
considers the contamination case and the pharmaceutical processes
blamed for the incident.
A drug that holds the potential to 'significantly' improve the
symptoms of rheumatoid arthritis (RA), rather than merely relieve
the pain for the debilitating disorder, is one step
closer to the market.